Oncopeptides AB (STO:ONCO), a pharmaceutical company developing drugs for the treatment of cancer, announced on Wednesday that data from its phase 1/2 O-12-M1 study evaluating melflufen, a lipophilic peptide-conjugated alkylator belonging to the novel class of peptidase enhanced cytotoxics, in the treatment of relapsed/refractory multiple myeloma (RRMM), have been selected for poster presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place between 31 May 2019 to 4 June 2019 in Chicago.
Reportedly, this data offers an analysis of time to next treatment (TTNT) in patients with RRMM who were treated with melflufen and dexamethasone in the phase 1/2 clinical study named O-12-M1. TTNT is used in Real World Evidence to assist treatment decisions and support economic reimbursement modelling.
According to the company, the early-stage clinical data being presented offer insights into the potential clinical application and utilisation of melflufen, which is also being studied now in the global, phase 3 OCEAN trial.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business